Expert Opinion on Pharmacotherapy

Article	Citations
Perspectives on the pharmacological management of dystonia	52
Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer	35
Intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis	35
Elucidating the mechanisms and efficacy of antimalarial drugs in systemic lupus erythematosus	34
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges	29
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis	28
GLP-1 receptor agonists: new kids in the block of renoprotection for people with type 2 diabetes and chronic kidney disease	28
Fixed-dose combination amlodipine–celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation	28
Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes	27
An update on emerging pharmacological treatments for meibomian gland dysfunction	25
The pharmacotherapeutic management of pulmonary tuberculosis: an update of the state-of-the-art	25
Asthma management with triple ICS/LABA/LAMA combination to reduce the risk of exacerbation: an umbrella review compliant with the PRIOR statement	24
Clinical guidance for unfractionated heparin dosing and monitoring in critically ill patients	23
The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease	22
Pharmacotherapy developments in autophagy inhibitors for bladder cancer	21
An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date	21
The state-of-the-art pharmacotherapeutic management of neovascular age-related macular degeneration	21
Immunosuppression in uterus transplantation: from transplant to delivery	20
Efficacy and safety of Isavuconazole for the treatment of invasive Aspergillus infection - an update of the literature	20
Use of antibiotics in hospitalized patients with COVID-19: evolving concepts in a highly dynamic antimicrobial stewardship scenario	20
Pharmacotherapeutic options for the treatment of menopausal symptoms	19
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes	19
Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma?	19
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19	18
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?	18

Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy	18
Pharmacological management of co-morbid obstructive sleep apnoea and insomnia	17
Response to: “the impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19”	17
An update on the pharmacological management of acute respiratory distress syndrome	17
Prescribing the right therapy for the treatment of chronic cough: a critical focus on current and investigational options	16
Calcium, magnesium, potassium, and sodium oxybates oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy	16
An update on pharmacotherapies for colorectal cancer: 2023 and beyond	16
An update on the use of pharmacotherapy for opioid-induced bowel dysfunction	16
Examining linaclotide for the treatment of chronic idiopathic constipation	16
Should we discontinue RAS-inhibitor therapy in patients with advanced CKD?	14
Novel pharmacotherapy targeting the positive symptoms of schizophrenia	14
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis	14
How does a clinician approach the pharmacological management of opioid use disorders in pregnant women and pregnant people?	14
Acalabrutinib in chronic lymphocytic leukemia	14
The pharmacological treatment and management of hyperhidrosis	13
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy	13
Choosing the appropriate pharmacotherapy for breast cancer during pregnancy: what needs to be considered?	13
Advances in pharmacotherapy for heart failure and reduced ejection fraction: what’s new in 2024?	12
An overview of adapalene and benzoyl peroxide once-daily topical gel as a therapeutic option for acne	12
An evaluation of setmelanotide injection for chronic weight management in adult and pediatric patients with obesity due to Bardet–Biedl syndrome	12
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization	12
Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review	12
An overview of micafungin as a treatment option for invasive candidiasis in pediatric patients younger than 4 months old	12
Tafenoquine for the treatment of Plasmodium vivax malaria	11
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B	11
Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant	11
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children	11
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults	11
A new role for an old drug: acetazolamide in decompensated heart failure	10
The pharmacotherapeutic management of nail unit and acral melanomas	10
Risk management of medication errors: a novel conceptual framework	10
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases	10
Evaluating upadacitinib for the treatment of psoriatic arthritis	10
Aripiprazole IM depot as an option for the treatment of bipolar disorder	10
Pharmacological management of migraine: current strategies and future directions	10
Pharmacotherapeutic options for cancer cachexia: emerging drugs and recent approvals	9
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook	9
Dapagliflozin for the treatment of type 2 diabetes mellitus – an update	9
Advances in pharmacotherapy for head and neck cancer	9
Will elinzanetant, a neurokinin receptor antagonist, have a role in the treatment of hot flashes?	9
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan	9
Advances in the pharmacological management of bacterial peritonitis	9
Addressing negative symptoms of schizophrenia pharmacologically with cariprazine: evidence from clinical trials, a real-world study, and clinical cases	9
An update on pharmacotherapy for fungal infections in allogeneic stem cell transplant recipients	9
Perspectives on the pharmacological management of complex regional pain syndrome	9
Nonselective proteasome inhibitors in multiple myeloma and future perspectives	9
Current and emerging treatment modalities for fibrodysplasia ossificans progressiva	9
Pharmaceutical management of sexual dysfunction in men on antidepressant therapy	9
An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer	9
Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance	9

Cytokine release syndrome after CAR T-cell therapy for B-cell acute lymphoblastic leukemia in children and young adolescents: storms make trees take deeper roots	9
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review	9
Historical milestones and future horizons: exploring the diagnosis and treatment evolution of the pulmonary arterial hypertension in adults	9
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives	9
How do we address treating the negative symptoms of schizophrenia pharmacologically?	9
The future of topical JAK inhibitors in the treatment of atopic dermatitis	9
Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer	9
How should a physician assess medication burden and polypharmacy?	9
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis	9
Novel pharmacotherapies for the treatment of liposarcoma: a comprehensive update	8
Pharmacotherapy for post-stroke aphasia: what are the options?	8
What are the key challenges in the pharmacological management of cholangiocarcinoma?	8
The correlations between steady-state concentration, duration of action and molecular weight of GLP-1RAs and their efficacy and gastrointestinal side effects in patients with type 2 diabetes mellitus:	8
An update on the pharmacotherapy of gout	8
Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease	8
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy	8
Cytopenic myelofibrosis: prevalence, relevance, and treatment	8
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease	8
Current optimal pharmacologic therapies for overactive bladder	8
An update on the efficacy of Venetoclax for chronic lymphocytic leukemia	8
Evolution of antiplatelet therapy in Japan for the management of cerebrovascular and cardiovascular disease: a survey using data from an insurance claims data information service	8
Letter to the editor – ‘Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia’	8
Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors	7
Advances in the pharmacological management of cutaneous T-cell lymphoma	7
Amyloidosis of the heart: pathophysiology, diagnosis, and treatment	7
What must be considered when prescribing hormonal pharmacotherapy for male infertility?	7
Evaluating bexicaserin for the treatment of developmental epileptic encephalopathies	7
New pharmacotherapeutic options for oral anticoagulant treatment in atrial fibrillation patients aged 65 and older: factor XIa inhibitors and beyond	7
Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy	7
Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants	7
An update on antifungal resistance in dermatophytosis	7
Psychedelics for treatment resistant depression: are they game changers?	7
Evaluating fostemsavir as a therapeutic option for patients with HIV	7
Pharmacotherapy considerations for morning symptoms in chronic obstructive pulmonary disease	7
An update on the current and emerging pharmacotherapy for the treatment of human ascariasis	7
Pharmacological treatment for children with constipation: present and future	7
Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia	7
Correction	7
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond	7
Bexagliflozin for type 2 diabetes: an overview of the data	7
Advances in the drug management of basal cell carcinoma	7
Current treatment options for Mycobacterium marinum cutaneous infections	7
The pharmacological management of treatment-resistant depression: what does the future hold?	7
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia	7
A bitter pill to swallow: adjustments to oral contraceptive pill use in polycystic ovary syndrome	7
Addressing the long-term risks of administering antenatal steroids	7
Careful use to minimize adverse events of oral antidiabetic medications in the elderly	7
Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?	7
Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials	7
Considerations for single- versus multiple-drug pharmacotherapy in the management of painful diabetic neuropathy	6
Advances in the pharmacotherapeutic management of post-traumatic stress disorder	6
Selecting appropriate therapy for lower-risk myelodysplastic syndromes: current state and future prospects	6
Cardiovascular risk of hormone replacement therapy in menopausal women with diabetes: a systematic review and meta-analysis of clinical trials and observational studies	6
Terlipressin in the management of liver disease	6
Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus	6
Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults	6
Advances in non-hormonal pharmacotherapy for the treatment of male infertility: the role of inositols	6
How to reduce medication errors in patients over the age of 65?	6
Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity	6
The pharmacotherapeutic management of allergic rhinitis in people with asthma	6
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?	6
Pharmacotherapy of persistent genital arousal disorder/genito-pelvic dysesthesia: an updated review and data from a registry	6
Identifying the challenges for successful pharmacotherapeutic management of sarcopenia	6
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma	6
Has the utilization of serotonin receptor antagonism made an impact on schizophrenia treatment?	6
Guidance for the pharmacological management of COVID-19 in the emergency setting	6
Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?	6
Glasdegib for the treatment of acute myeloid leukemia	6
What are the considerations for the pharmacotherapeutic management of acute promyelocytic leukemia in children?	6
Advances in pharmacotherapy for sickle cell disease: what is the current state of play?	6
Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder	6
Advances in the pharmacological management of acute myeloid leukemia in adults	6
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults	6
Why are sodium channel modulators not yet pharmacotherapeutic trailblazers for neuropathic pain?	6
Current pharmacotherapy of cryptosporidiosis: an update of the state-of-the-art	6
An evaluation of sebetralstat as the first oral on-demand therapy for hereditary angioedema	6
Advances in non-biological drugs for the treatment of rheumatoid arthritis	6
The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?	6
Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease	6
Clinical guidance for choosing the right pharmacotherapy for migraine attacks	6

Developments in conservative treatment for BCG-unresponsive non-muscle invasive bladder cancer	6
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis	5
Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?	5
How useful is chemotherapy for atypical and anaplastic meningiomas?	5
Odevixibat: a promising new treatment for progressive familial intrahepatic cholestasis	5
Current and emerging treatment modalities for bacterial rhinosinusitis in adults: a comprehensive review	5
When is pharmacotherapy necessary for the treatment of seasonal affective disorder?	5
Cannabidiol use in patients with Dravet syndrome and Lennox-Gastaut syndrome: experts’ opinions using a nominal group technique (NGT) approach	5
The complement system: a novel therapeutic target for age-related macular degeneration	5
Advances in small molecule maintenance therapies for high-grade serous ovarian cancer	5
Current unmet needs and emerging novel pharmacotherapies in psoriatic arthritis	5
Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer	5
Managing the neuroinflammatory pain of endometriosis in light of chronic pelvic pain	5
New pharmacotherapeutic strategies for drug-resistant Candida infections: a review	5
Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II	5
Azole resistance in Aspergillus species: promising therapeutic options	5
Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces?	5
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy	5
What is the real value of metronomic chemotherapy in the treatment of gastrointestinal cancer?	5
Testosterone replacement therapy: clinical considerations	5
An up-to-date overview of the pharmacotherapeutic options for premature ejaculation	5
What are the considerations for the treatment of multidrug resistant Acinetobacter baumannii infections?	5
Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go?	5
Evaluating lemborexant for the treatment of insomnia	5
State-of-the-art beta-adrenoreceptor agonists for the treatment of asthma	5
Adding liraglutide to diet and exercise to maintain weight loss – is it worth it?	5
An expert opinion on the pharmacological interventions for Disruptive Mood Dysregulation Disorder (DMDD)	5
Pharmacotherapy in leishmaniasis: old, new treatments, their impacts and expert opinion	5
Current and emerging pharmacotherapy for menstrual migraine: a narrative review	5
Advances in pharmacotherapy for the treatment of peritoneal metastases from colorectal cancer	5
Zanubrutinib for the treatment of chronic lymphocytic leukemia	5
An evaluation of sotorasib for the treatment of patients with non–small cell lung cancer with KRASG12C mutations	5
How effective is pharmacotherapy for stroke and what more is needed? A focus on atrial fibrillation	5
Medications to manage infant pain, distress and end-of-life symptoms in the immediate postpartum period	5
How do you treat obesity in the elderly pharmacologically?	5
The Park Sleep subtype in Parkinson’s disease: from concept to clinic	5
Rise and fall of decongestants in treating nasal congestion related diseases	5
Correction	5
Improving adherence with treatment-resistant hypertension	5
What value do cell cycle inhibitors have in the treatment of myelodysplastic syndrome?	5
Vibegron for the treatment of overactive bladder: a comprehensive update	5
Momelotinib in myelofibrosis	5
Aztreonam-avibactam for the treatment of intra-abdominal infections	4
The pharmacotherapeutic management of duodenal and gastric ulcers	4
Promising advances in treatments for the management of idiopathic pulmonary fibrosis	4
An update on brivaracetam for the treatment of pediatric partial epilepsy	4
Advances with pharmacotherapy for the treatment of interstitial lung disease	4
The current possibilities of diagnosing and therapies for olfactory disorders	4
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants	4
When is it appropriate to treat children with social anxiety, pharmacologically?	4
Pharmacological management of secondary spinal cord injury	4
A review of therapeutic failures in late-stage clinical trials	4
PSMA-based therapeutics for prostate cancer	4
Advances in pharmacotherapy for bronchiectasis in adults	4
Metabolic-associated steatotic liver disease and hepatocellular carcinoma	4
Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)	4
Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?	4
How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients?	4
Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia	4
An update in the pharmacological management of axial spondyloarthritis	4
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy	4
Complicated urinary tract infections: an update of new and developing antibiotics	4
The state-of-the-art pharmacotherapeutic options for the treatment of chronic non-cancer pain	4
Current and emerging pharmacotherapeutic strategies for Tourette syndrome	4
Emerging therapies targeting growth factors in hepatocellular carcinoma	4
Pharmacotherapeutic options in the treatment of nocturia: an update on the current oral drug therapies	4
Ospemifene and vulvovaginal atrophy: an update of the clinical profile for post-menopausal women	4
Pharmacotherapeutic options in pediatric obesity: an urgent call for further research	4
Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review	4
Pharmacotherapy of residual excessive sleepiness among continuous positive airway pressure (CPAP) treated patients with sleep apnea	4
Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients	4
Update on current pharmacologic therapies for diabetic retinopathy	4
Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer’s disease: a novel small molecule with disease modifying potential	4
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis	4
An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis	4
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia	4
Therapeutic orphans, off-label, pediatric drug development: towards reasonable pharmacotherapy for minors	4
The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium	4
Update on the pharmacological treatment of chronic obstructive pulmonary disease	4
Exploring odevixibat’s efficacy in alagille syndrome: insights from recent clinical trials and IBAT inhibitor experiences	4
Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer	4
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments	4
Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions	4
An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer	4
A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)	4
Current chemotherapeutic options for the treatment of gestational trophoblastic disease	4
Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors	4
Efficacy and tolerability of pharmacotherapy for obsessive-compulsive personality disorder: a systematic review of randomized controlled trials	4
Talazoparib for the treatment of prostate cancer	4
Pharmacological strategies for improving the prognosis of glioblastoma	4
Selinexor in multiple myeloma	4
Upadacitinib in Crohn’s disease: needs more insight	4
Advances in drug treatments for mesothelioma	4
New cytomegalovirus antiviral therapy: unlocking future prospects in treating cytomegalovirus-induced hemophagocytic lymphohistiocytosis	4
Expanding therapeutic options: lenacapavir + bictegravir as a potential treatment for HIV	4